Vyleesi Vaccine Interaction Profile: What Women Need to Know Before and After Each Dose

What Is Bremelanotide (Vyleesi) and Why Interactions Matter

Bremelanotide is a melanocortin-receptor agonist that the FDA approved in August 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts on MC1R and MC4R receptors in the central nervous system to increase sexual desire before an anticipated sexual event. You inject it subcutaneously in the abdomen or thigh 45 minutes before activity, as needed.

Because Vyleesi is used on-demand rather than daily, many women assume it cannot interact with other medications or medical interventions. That assumption is only partly correct. While the molecule itself does not bind to cytochrome P450 enzymes in a way that meaningfully alters vaccine immunogenicity, the drug's side-effect profile overlaps with common post-vaccination symptoms in ways that matter clinically.

How Bremelanotide Is Processed in the Body

Bremelanotide is metabolized via peptide hydrolysis, not through CYP3A4, CYP2D6, or other major hepatic oxidative pathways. Published pharmacokinetic data show a half-life of approximately 2.7 hours, with most systemic exposure cleared within 12 hours. This metabolic profile means classic drug-drug interactions involving CYP inhibition or induction are not expected.

The drug is also not a P-glycoprotein substrate or inhibitor, and it does not affect plasma protein binding of co-administered drugs at clinically relevant concentrations. These characteristics are actually reassuring: the molecule is unlikely to alter vaccine antigen processing, adjuvant activity, or the immune response that generates protective antibody titers.

Why Timing Still Matters

What the pharmacokinetic profile does not tell you is the full picture. Bremelanotide reliably produces nausea in approximately 40% of women in the first one to three hours after injection, along with flushing (20%), injection-site bruising (14%), headache (11%), and a transient rise in blood pressure averaging +6 mmHg systolic and +5 mmHg diastolic, peaking at about 12 minutes and resolving within 12 hours. Many vaccines, particularly adjuvanted influenza vaccines and COVID-19 mRNA vaccines, also produce systemic reactogenicity including fatigue, myalgia, headache, and low-grade fever within 6 to 24 hours of injection.

If you use Vyleesi and receive a vaccine on the same day, distinguishing a drug side effect from a vaccine reaction becomes genuinely difficult. A clinician who does not know you used Vyleesi that evening might attribute tachycardia or nausea to an anaphylactic prodrome and initiate unnecessary treatment. Conversely, a true post-vaccine systemic reaction could be dismissed as "just the Vyleesi." Clear separation by at least 24 hours removes this diagnostic ambiguity.

The Vaccine Interaction Evidence: What the Label Says and What It Does Not

The current FDA-approved prescribing information for bremelanotide does not list any vaccine as a contraindication, precaution, or interaction. The drug-interaction section focuses on naltrexone (reduced absorption when co-administered), indomethacin (modest PK changes), and the general note that transient blood-pressure increases could be additive with vasoconstrictors. Vaccines are not discussed.

No randomized controlled trial has specifically studied bremelanotide co-administered with any vaccine schedule. This is a genuine evidence gap, and it is worth naming clearly. The absence of listed interactions reflects the absence of dedicated studies, not a definitive finding of safety.

What We Can Reasonably Conclude

Given the peptide-hydrolysis metabolism and the absence of immune-modulating mechanism, there is no theoretical pharmacological basis to expect that Vyleesi will blunt vaccine-induced antibody production or increase vaccine adverse-event rates. Melanocortin receptors do play a role in peripheral inflammatory signaling, and MC1R activation has been shown in animal models to have anti-inflammatory effects. Whether this has any clinically measurable impact on vaccine immunogenicity in humans has not been studied.

The WomanRx clinical framework for on-demand drugs with systemic side effects near vaccine days follows three principles:

1. Separate timing by at least 24 hours when the drug produces systemic reactogenicity overlapping with common vaccine reactions.
2. Inform your vaccinating provider that you used the drug within the prior 24 hours if separation was not possible, so that any adverse event is interpreted correctly.
3. Do not delay a clinically urgent vaccine (rabies post-exposure, tetanus after injury) solely because of Vyleesi use. The pharmacological interaction risk is low; the risk of delayed vaccination may be significant.

Specific Vaccine Categories

Influenza vaccines. Adjuvanted high-dose influenza vaccines (Fluzone High-Dose Quadrivalent, Fluad Quadrivalent) cause injection-site pain, myalgia, and low-grade fever in a meaningful proportion of women over 65. Because Vyleesi is approved only for premenopausal women, the clinical overlap is less common in the age groups most likely to receive adjuvanted formulations. Standard-dose inactivated influenza vaccines produce milder systemic reactions, and a 24-hour spacing is a reasonable precaution rather than a strict requirement.

COVID-19 mRNA vaccines. The second dose of the original Pfizer-BioNTech and Moderna primary series, and updated bivalent or monovalent boosters, produce systemic reactogenicity (fatigue, headache, myalgia, chills) in roughly 50 to 70% of recipients within 24 hours. Spacing Vyleesi use at least 24 hours before or after a COVID-19 vaccine dose is the most practical recommendation.

Human papillomavirus (HPV) vaccines. Gardasil 9 is recommended through age 26 for all women and through age 45 for women who were not previously vaccinated. ACOG recommends discussing HPV vaccination through age 45 in shared decision-making conversations. The systemic reactogenicity of Gardasil 9 is generally mild, but local injection-site pain and dizziness, including vasovagal syncope, are documented. Because Vyleesi itself can cause transient hypotension in some women, combining it with a vaccine known to occasionally trigger vasovagal reactions on the same day adds unnecessary overlap.

Shingles vaccine (Shingrix). Shingrix (recombinant zoster vaccine) causes systemic reactions in a majority of recipients, with grade-3 reactions in approximately 17%. This vaccine is recommended for women over 50. Vyleesi is not currently approved or studied in postmenopausal women, so direct clinical overlap in the same patient is unlikely under current labeling. If an off-label discussion arises, the same 24-hour spacing principle applies.

Alcohol and Vyleesi: A Separate but Connected Concern

"Can I drink on Vyleesi?" is one of the most commonly searched questions about this drug. The answer requires nuance.

The FDA label does not list alcohol as a contraindicated combination, and there is no published pharmacokinetic study of bremelanotide co-administered with ethanol. However, the drug's hemodynamic profile creates a practical concern. Bremelanotide transiently raises blood pressure, and alcohol, depending on dose and timing, generally lowers it through vasodilation. The net effect in any individual woman is unpredictable.

More clinically relevant is the nausea overlap. Vyleesi-induced nausea severe enough to require antiemetics occurred in about 13% of women in phase 3 trials. RECONNECT, the key phase 3 program, enrolled 1,247 premenopausal women across two 24-week trials. Alcohol, even in modest amounts, lowers the nausea threshold independently. Combining both on the same evening substantially increases the likelihood of a difficult experience.

The practical guidance: if you plan to use Vyleesi, limit alcohol to one standard drink or fewer that evening. Do not use Vyleesi if you have already consumed three or more drinks, because the combination of impaired judgment, vasodilation, and Vyleesi-induced nausea and blood-pressure changes represents a more complex physiological situation than either alone.

Pregnancy, Lactation, and Contraception: Required Reading

This section is mandatory reading for any woman of reproductive age using Vyleesi.

Pregnancy

Bremelanotide is contraindicated in pregnancy. Animal reproductive studies showed dose-dependent darkening of fetal fur pigmentation at exposures approximating human therapeutic doses, reflecting MC1R activity. The FDA label explicitly states that bremelanotide should be discontinued if pregnancy is confirmed, and women should stop using the drug at least one full menstrual cycle before attempting conception.

The label carries no formal pregnancy category under the modern Pregnancy and Lactation Labeling Rule, but the prescribing information section 8.1 notes that animal data showing melanocortin-related pigmentation changes cannot exclude potential developmental risk in humans. Because the drug is used on-demand rather than daily, inadvertent first-trimester exposure may occur before a woman realizes she is pregnant. If you are trying to conceive, Vyleesi is not appropriate. If you are sexually active and not using reliable contraception, discuss this with your provider before your first dose.

Lactation

No human data on bremelanotide transfer into breast milk exist. The FDA label advises against use during breastfeeding. Given the peptide nature of the molecule and its relatively short half-life (approximately 2.7 hours), theoretical transfer into milk, and likely infant oral bioavailability through the gut, is probably low. However, "probably low" is not the same as studied and confirmed. Until lactation data emerge, breastfeeding women should not use Vyleesi.

Contraception Considerations

Because Vyleesi is approved only for premenopausal women and is used precisely in the context of sexual activity, contraception planning is directly relevant. The drug does not appear to affect the efficacy of hormonal contraceptives based on available PK data, but no dedicated drug-interaction study with combined oral contraceptives or progestin-only methods has been published. If you use a combined hormonal method containing ethinyl estradiol, there is no current evidence to suggest Vyleesi alters its effectiveness. Use your chosen contraceptive method as prescribed, independently of Vyleesi dosing timing.

Who Should and Should Not Use Vyleesi: A Life-Stage View

Reproductive-Age Women (Premenopausal, Not Trying to Conceive)

This is the approved population. HSDD in this group may be primary (lifelong) or secondary, often emerging after a major hormonal event such as starting or stopping hormonal contraception, postpartum recovery, or the onset of depression. Vyleesi addresses the desire-phase disorder specifically. It does not treat arousal disorder, orgasm disorder, or pain with intercourse, which are distinct diagnoses.

Women in this group who receive regular vaccines (annual influenza, COVID-19 boosters, Tdap if postpartum) should simply space Vyleesi away from vaccine days by 24 hours and note their Vyleesi use in their health records so that a vaccinating provider has context.

Trying to Conceive

Stop Vyleesi. There is no safe window of use during a conception cycle based on current data.

Postpartum and Breastfeeding

Stop Vyleesi until you have stopped breastfeeding and have resumed regular menstrual cycles, at which point a conversation with your OB-GYN about whether HSDD in the postpartum context is the right diagnosis is warranted. Postpartum low desire is extremely common and is often driven by prolactin elevation, estrogen suppression, sleep deprivation, and relational adjustment. These causes do not require a pharmacologic desire agent; they require addressing the root physiology and circumstances.

Perimenopause

Vyleesi is not approved for perimenopausal or postmenopausal women. The key RECONNECT trials enrolled premenopausal women only. HSDD is equally prevalent and arguably underdiagnosed in perimenopausal women, but the evidence base for bremelanotide in this group is absent. If you are perimenopausal and experiencing HSDD, the evidence-based conversation starts with addressing vasomotor symptoms and genitourinary syndrome of menopause (GSM) first, since these conditions independently suppress desire.

The Menopause Society (formerly NAMS) 2022 position statement on sexual health in menopause does not include bremelanotide as a recommended option for postmenopausal women given the absent trial data in this population.

Postmenopause

Off-label use in postmenopausal women is not supported by clinical trial evidence and the label explicitly limits the indication to premenopausal women. Discuss alternative evidence-based options for postmenopausal HSDD with a NAMS-certified provider.

Other Drug Interactions Worth Knowing

Beyond vaccines and alcohol, the Vyleesi label and available pharmacology literature identify several other interactions relevant to women.

Naltrexone

Co-administration of bremelanotide with oral naltrexone reduced naltrexone exposure by approximately 35%, based on pharmacokinetic data cited in the prescribing information. Naltrexone is used for alcohol use disorder, opioid use disorder, and as the naltrexone component of bupropion-naltrexone (Contrave) for weight management. If you take any of these, discuss the interaction with your prescriber. The clinical significance depends on your naltrexone dose and indication.

Indomethacin

Concomitant use of indomethacin (an NSAID) increased bremelanotide maximum concentration by approximately 19% and area-under-the-curve by 25% in formal PK studies. This is not a contraindication, but it suggests women who take indomethacin for dysmenorrhea, chronic pelvic pain, or rheumatologic conditions may experience somewhat more intense or prolonged Vyleesi effects on dosing days.

Antihypertensives and Cardiovascular Drugs

The transient blood-pressure increase from Vyleesi is modest on average (+6/+5 mmHg), but individual variation is wide. Women with pre-existing cardiovascular disease, uncontrolled hypertension, or those taking drugs with narrow hemodynamic margins should discuss Vyleesi use with their cardiologist or internist before starting. The FDA label advises checking blood pressure after each injection and pausing subsequent doses if a meaningful rise occurs.

Drugs That Slow Gastric Emptying

Vyleesi slows gastric emptying, which means that medications taken orally around the same time as a Vyleesi injection may be absorbed more slowly. If you take a time-sensitive oral medication (levothyroxine for hypothyroidism, for example), dose it at least two hours before your Vyleesi injection and do not time a new oral dose immediately after.

Hormonal Contraceptives

As noted in the pregnancy section, no dedicated interaction trial with combined hormonal contraceptives has been published. The gastric-emptying slowing effect is the most theoretically relevant: if a combined oral contraceptive pill is taken on the same evening as a Vyleesi injection, absorption could be delayed. Space your daily OCP at least two hours before or after your Vyleesi injection on those evenings, as a practical precaution.

Managing Side Effects That Overlap With Vaccine Reactions

Women using Vyleesi and receiving vaccines should have a simple framework for distinguishing side effects.

Vyleesi-specific timing: Symptoms appear within 45 to 60 minutes of injection and largely resolve within three to four hours, with blood-pressure changes resolving within 12 hours. If symptoms persist beyond 12 to 24 hours after a Vyleesi dose, Vyleesi is almost certainly not the cause.

Vaccine-specific timing: Systemic vaccine reactions from inactivated vaccines (influenza, HPV, Shingrix) typically begin 6 to 12 hours after injection and peak at 24 to 48 hours. MRNA vaccine systemic reactogenicity often peaks 12 to 24 hours after the dose. Symptoms persisting more than 48 to 72 hours after vaccination warrant clinical evaluation regardless of Vyleesi use.

When to seek immediate care: Hives, throat tightening, wheezing, or severe hypotension within 15 to 30 minutes of any injection, whether Vyleesi or vaccine, require emergency evaluation. These are signs of anaphylaxis and neither Vyleesi nor vaccines are completely free of this risk. Always remain at a vaccine administration site for 15 minutes after injection. If you self-administered Vyleesi and develop urticaria or angioedema, call emergency services. These reactions are rare for both, but the overlap of two injectable products on the same day could complicate post-event attribution.

Practical Scheduling Guide for Women Using Vyleesi

Below is a straightforward approach organized by scenario.

Routine vaccine appointment (influenza, COVID-19 booster, Tdap): Do not use Vyleesi on the day before your vaccine, the day of your vaccine, or the evening of your vaccine. Resume use 24 hours after vaccination once you know how your body responded to the shot.

HPV vaccine series (Gardasil 9, three-dose or two-dose schedule): The same 24-hour spacing applies. HPV vaccine appointments can be planned well in advance, so scheduling is easy. Note the vaccine date in your calendar and plan Vyleesi use accordingly.

Unexpected same-day situation: If you received a vaccine earlier in the day and feel systemically well (no fever, no significant fatigue), the pharmacological argument against using Vyleesi that same evening is theoretical rather than evidence-based. The stronger reason to wait is diagnostic clarity, not direct toxicity. Tell your partner or someone nearby that you have used Vyleesi so that any unexpected symptom is reported in context.

Urgent vaccine (post-injury tetanus, post-exposure rabies series): Do not delay life-protecting vaccination because of Vyleesi. The interaction risk is theoretical and low; the risk of, for example, rabies without post-exposure prophylaxis is not theoretical. Use Vyleesi at least 24 hours before or after each dose in the series when clinically possible.

The Evidence Gap: What Women's Health Trials Have Not Answered

Women have been underrepresented in pharmacokinetic drug-drug interaction studies for decades, and Vyleesi is no exception to this broader problem in a different way: it is approved exclusively for women, yet vaccine co-administration has never been studied in the key trials or in post-marketing safety data published to date.

The RECONNECT program enrolled 1,247 premenopausal women across Study 1 and Study 2, with a 24-week double-blind treatment period followed by a 52-week open-label extension. Adverse-event reporting captured systemic side effects but did not systematically track concomitant vaccine administration or vaccine-related adverse events.

This gap matters because women using Vyleesi are in their reproductive years, a life stage associated with multiple vaccine-preventable illness exposures, routine immunization updates (influenza, COVID-19 boosters, potential Tdap in preconception planning), and sometimes accelerated vaccination needs during family planning conversations. The absence of data is not reassuring; it is simply absent. Clinicians should not assume safety has been established simply because interactions were not observed in trials that were not designed to detect them.

ACOG Committee Opinion 809 and broader ACOG immunization guidance emphasize that reproductive-age women should stay current with all recommended vaccines. Women using Vyleesi should receive that same guidance, with the practical timing note above.